Moving towards insulin-free T1D
Moving towards insulin-free T1D
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
OKLearn moreWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy
New Resources Now Available for Researchers
20 November 2025
We’re pleased to announce three new interactive dashboards for researchers working in Type 1 diabetes:
All three resources are now available on our For Researchers page.
For further information, contact T1DUK@cardiff.ac.uk.
World Diabetes Day 2025: EMA Recommends First Treatment to Delay Type 1 Diabetes Onset
Date: 19 November 2025
World Diabetes Day 2025 has brought encouraging news for the type 1 diabetes community. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of teplizumab (Tzield) for patients with stage 2 type 1 diabetes.
This marks a significant milestone as the first-in-class treatment designed to delay the onset of stage 3 type 1 diabetes. The recommendation follows clinical evidence demonstrating teplizumab’s potential to postpone disease progression in at-risk individuals.
The CHMP’s positive opinion is an important step towards making this treatment available to patients across Europe. Final approval from the European Commission is now awaited.
Further Information:
Applications Open for EASD’s 1st Immunology School for Endocrinology in Vienna
Date: 14.11.2025
The European Association for the Study of Diabetes (EASD) is accepting applications for its inaugural Immunology School for Endocrinology, taking place on 26-27 March 2026 in Vienna, Austria.
This two-day educational programme offers an excellent opportunity for researchers and clinicians working in diabetes and endocrinology to deepen their understanding of immunological mechanisms.
How to Apply: Applications are now open. For full details and to apply, visit the EASD Immunology School webpage.
New drug trial offers hope for slowing type 1 diabetes progression
A groundbreaking clinical trial has shown that the drug teplizumab can delay the onset of type 1 diabetes by an average of two years in high-risk individuals. The treatment, which targets the immune system, offers hope for those identified as being at risk of developing the condition. Researchers describe it as a “pivotal moment” in type 1 diabetes care, though caution that more work is needed to understand long-term effects and accessibility.
Read more at BBC News
MHRA approves teplizumab to delay progression of type 1 diabetes
Type 1 diabetes (T1D) research is at a pivotal point – there is now a licensed therapy in the UK, Teplizumab, to delay onset of symptoms in people with early stage T1D (Link).
Over decades, our UK-based research, both academic and commercial has made a major contribution to identifying children and adults who will develop type 1 diabetes symptoms in the future (Link to studies).
There is now one treatment to delay, but additional research will identify even better treatments leading to our vision of insulin free type 1 diabetes.
More detailed coverage of the news is available here.
Are we proof that a new drug to stop type 1 diabetes really does work?
A new drug for Type 1 diabetes, Teplizumab, is being tested in the PROTECT clinical trial.
Teplizumab blocks the action of insulin-destroying antibodies in type 1.
Read the article on the Daily Mail
The ELSA Study
The ELSA study launched nationally on World Diabetes Day in November 2022. Within 24 hours, over 1000 children were signed-up to the study! By February 2023, we have sent over 3000 home-testing kits out to families and have analysed over 1000 kits so far. The next phase of the study is to disseminate to schools and general practices across the UK. A huge thank you to the parents and children who have taken part in the ELSA study. If you would like to find out more about screening your child for type 1 diabetes, visit: https://www.elsadiabetes.nhs.uk/.
Readily Available Drug Shows Promise in Treating Type 1 Diabetes
Study shows verapamil can have a beneficial effect on the pancreas in children with newly diagnosed type 1 diabetes.
Find out more from this article
First Treatment to Delay Type 1 Diabetes Licensed in the US
On 17/11/22 teplizumab was approved by the US Food and Drug Administration (FDA) as the first ever treatment indicated to delay the onset of stage 3 type 1 diabetes. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago.
Although teplizumab is not approved in the UK yet, the US approval paves the way for this life-changing treatment to be made available to people at high risk of developing type 1 diabetes in the UK too.
Listen to this Podcast
Find out more
Mahn’s story: taking part in immunotherapy research
An 11 year old’s story of taking part in immunotherapy research: Mahn was diagnosed with type 1 diabetes in May 2020. His parents Sharon and Harj were determined to get him onto a clinical trial testing a new treatment called immunotherapy, which hopes to slow the immune attack behind type 1 diabetes. Please click the link to Mahn’s story where he shares his experience of his diagnosis, treatments and life with diabetes.
Visit the full story here >